Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Health Reform Will Nurture New Drugs, While Boosting Use Of Old Ones - PharmAsia Summit

This article was originally published in The Pink Sheet Daily

Executive Summary

Veteran of Chinese health regulation outlines ABC's of the changes sweeping the vast nation at PharmAsia Summit.

You may also be interested in...



How Bayer Secured the Top-Spot in China: An Interview with Liam Condon

A focus on older, primary care brands--initially running contrary to Bayer Schering's group strategy post-merger--was key to the company's reaching its leadership position in China. Liam Condon, Managing Director of Bayer HealthCare China, talks about the group's commercial success to date and its future plans, particularly to build up its R&D presence.

How Bayer Secured the Top-Spot in China: An Interview with Liam Condon

A focus on older, primary care brands--initially running contrary to Bayer Schering's group strategy post-merger--was key to the company's reaching its leadership position in China. Liam Condon, Managing Director of Bayer HealthCare China, talks about the group's commercial success to date and its future plans, particularly to build up its R&D presence.

Primary Care Focus Is Key To Bayer's Leading Position In China

Bayer Schering Pharma didn't become the number one health care company in China simply through the merger of Bayer and compatriot Schering AG in 2006. "The pure act of merging would not have been enough; we would only have been number six" in China, explains Liam Condon, managing Director of Bayer HealthCare China, which reported 2008 sales of over $750 million and over 50 percent growth

Related Content

Topics

UsernamePublicRestriction

Register

PS068685

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel